Which drugs are most likely to be approved in Mixed Pain (Nociceptive Pain/Neuropathic Pain)?

Mixed Pain (Nociceptive Pain/Neuropathic Pain) disease is an indication for drug development with over 270 pipeline drugs currently active according to GlobalData.

Sub-$100 genome sequencing the highlight of Complete Genomics’ 18th anniversary milestone

Ever since The Human Genome Project was completed in 2003, the development of tools to uncover valuable insights from genetic data sets has evolved, driven

June 15, 2023

4 steps to minimize the threat of legacy medical devices

Listen to the article 12 min This audio is auto-generated. Please let us know if you have feedback. The Food and Drug Administration implemented sweeping

September 23, 2024

Highlights from the EHA Congress 2023 meeting: allogeneic cell therapy updates – Pharmaceutical Technology

For blood cancers, GlobalData’s Pharma Intelligence Center (PIC) lists 58 alloCAR-T products and 129 clinical trial programmes. Credit: Mesa Studios via Shutterstock. The development of

July 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.